Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting high risk disease using serum and DNA biomarkers.

Current opinion in urology - 1 May 2013

Vesprini Danny, Liu Stanley, Nam Robert

Abstract excerpt

PURPOSE OF REVIEW: To explore several serum and genetic-based biomarkers that may prove useful in following men being managed with active surveillance for localized prostate cancer by predicting those that either have the potential to develop, or already harbor occult high grade disease. RECENT FINDINGS: There is increasing evidence that serum biomarkers human Kallikrein 2, early prostate cancer antigen,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Disease Progression
Share to Neoplasm Grading

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Predictive Value of Tests

Share to Prognosis

Share to Prostatic Neoplasms

Share to Risk Assessment

Share to Time Factors

Source

Identifiers

PMID: 23449497
DOI: 10.1097/MOU.0b013e32835f89b8

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting high risk disease using serum and DNA biomarkers.PMID 23449497Read ↗

Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.Semantic proximity Read ↗

Diagnosis, staging, and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects.Semantic proximity Read ↗

Molecular markers in urologic oncology: prostate cancer.Semantic proximity Read ↗

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical PotentialSemantic proximity Read ↗

PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.Semantic proximity Read ↗

Defining high-risk prostate cancer: current status.Semantic proximity Read ↗

Biomarkers in Localized Prostate Cancer: Towards a Personalized MedicineSemantic proximity Read ↗

Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?Semantic proximity Read ↗

Prostate cancer: indicators of aggressiveness.Semantic proximity Read ↗

Kallikreins as Biomarkers for Prostate CancerSemantic proximity Read ↗

Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approachSemantic proximity Read ↗

Beyond blood biomarkers: the role of SelectMDX in clinically significant prostate cancer identificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.